NRXP - NASDAQ
NRx Pharmaceuticals, Inc.
$4.62
-12%NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
At a Glance
Live Snapshotnrxp
Other Current Liabilities
Last Annual Value
23.99M
3-Year CAGR
766%
5-Year CAGR
%
10-Year CAGR
124%
NRx Pharmaceuticals, Inc. Competitors Analysis of Other Current Liabilities
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
NRx Pharmaceuticals, Inc. NASDAQ:NRXP | 23.99M | 75.7% | 37.5% | N/A | |
 Equillium, Inc. NASDAQ:EQ | 1.82M | -20.7% | -11.7% | N/A | |
 Coeptis Therapeutics, Inc. NASDAQ:COEP | 161.05K | -33.8% | N/A | N/A | |
 Cue Biopharma, Inc. NASDAQ:CUE | 7.63M | 58.5% | 188.3% | 52.9% | |
 Aligos Therapeutics, Inc. NASDAQ:ALGS | 13.53M | 26.6% | 15.4% | N/A | |
 MediciNova, Inc. NASDAQ:MNOV | 2.61M | 38.2% | 36.7% | N/A | |
 OS Therapies Incorporated NYSE:OSTX | 2.35M | -20.7% | 7.8% | N/A | |
 Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | 12.21M | 46.8% | 78.9% | N/A | |
 Relmada Therapeutics, Inc. NASDAQ:RLMD | 4.86M | -5.1% | 24.3% | 25.2% | |
 Outlook Therapeutics, Inc. NASDAQ:OTLK | 45755.71B | 29164.0% | 2665.6% | 440.1% | |
 Werewolf Therapeutics, Inc. NASDAQ:HOWL | 33.64M | 110.1% | 190.4% | N/A |
NRx Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your NRXP research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.